[Updated] 世界の造影剤（コントラスト剤）市場動向（～2017）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 MARKET DYNAMICS
3.3.1 DRIVERS
3.3.1.1 INCREASING DEMAND FOR DIAGNOSTIC & IMAGE GUIDED PROCEDURES INFLUENCES CONTRAST MEDIA SALES
3.3.1.2 TECHNOLOGICAL ADVANCEMENTS TO SPUR THE CONTRAST MEDIA MARKET
3.3.1.3 INCREASING INCIDENCE & MORTALITY OF CANCER & CARDIAC DISEASES TO BOOST GROWTH OF CONTRAST MEDIA
3.3.1.4 GROWTH OF MEDICAL IMAGING TECHNOLOGY IN EMERGING MARKETS
3.3.2 RESTRAINTS
3.3.2.1 MAJOR ECONOMIES UNDERGOING HEALTHCARE REFORMS TO AFFECT THE SALES ON CONTRAST MEDIA
3.3.2.2 ECONOMIC SLOWDOWN TO INHIBIT GROWTH
3.3.3 OPPORTUNITIES
3.3.3.1 GROWING INVESTMENT POTENTIAL IN IMMATURE EMERGING MARKETS
3.3.3.2 ADVENT OF NOVEL CONTRAST AGENTS COMBINING PROPERTIES OF CONTRAST MEDIA & RADIOPHARMACEUTICALS
3.3.4 BURNING ISSUE – TOXICITY
3.3.4.1 NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
3.3.4.2 CONTRAST-INDUCED NEPHROTOXICITY (CIN)
3.3.5 TECHNOLOGY TRENDS
3.3.5.1 N1177 – A REVOLUTIONARY MACROPHAGE LABELING AGENT
3.3.5.2 SPAGO PIX – ACCURATE VISUALIZATION OF TUMORS WITH MRI
3.3.5.3 CMC-001 – FOCUSED ON LIVER MRI
3.4 MARKET SHARE ANALYSIS

4 BY PRODUCT
4.1 INTRODUCTION
4.2 BARIUM-BASED CONTRAST MEDIA
4.2.1 TECHNICAL OVERVIEW
4.2.2 MARKET DYNAMICS
4.2.3 MARKET ANALYSIS
4.3 IODINATED CONTRAST MEDIA
4.3.1 TECHNICAL OVERVIEW
4.3.2 MARKET DYNAMICS
4.3.3 MARKET ANALYSIS
4.3.4 TYPES – LOW-OSMOLAR AND HIGH-OSMOLAR
4.3.4.1 LOW-OSMOLAR CONTRAST MEDIA (LOCM)
4.3.4.1.1 TECHNICAL OVERVIEW
4.3.4.1.2 MARKET ANALYSIS
4.3.4.2 HIGH-OSMOLAR CONTRAST MEDIA (HOCM)
4.3.4.2.1 TECHNICAL OVERVIEW
4.3.4.2.2 MARKET ANALYSIS
4.4 GADOLINIUM-BASED CONTRAST MEDIA
4.4.1 TECHNICAL OVERVIEW
4.4.2 MARKET DYNAMICS
4.4.3 MARKET ANALYSIS

5 BY ROUTE OF ADMINISTRATION
5.1 INTRODUCTION
5.2 ORAL CONTRAST MEDIA
5.2.1 TECHNICAL OVERVIEW
5.2.2 MARKET DYNAMICS
5.2.3 MARKET ANALYSIS
5.3 INJECTABLE CONTRAST MEDIA
5.3.1 TECHNICAL OVERVIEW
5.3.2 MARKET DYNAMICS
5.3.3 MARKET ANALYSIS
5.3.4 INJECTABLE CONTRAST MEDIA – TYPES
5.3.4.1 INTRAVENOUS (IV)
5.3.4.2 INTRA-ARTERIAL (IA)
5.4 RECTAL CONTRAST MEDIA
5.4.1 TECHNICAL OVERVIEW
5.4.2 MARKET DYNAMICS
5.4.3 MARKET ANALYSIS
5.5 URETHRAL CONTRAST MEDIA
5.5.1 TECHNICAL OVERVIEW
5.5.2 MARKET DYNAMICS
5.5.3 MARKET ANALYSIS

6 BY MEDICAL PROCEDURE
6.1 INTRODUCTION
6.2 X-RAY
6.2.1 TECHNICAL OVERVIEW
6.2.2 MARKET DYNAMICS
6.2.3 MARKET ANALYSIS
6.3 COMPUTED TOMOGRAPHY (CT)
6.3.1 TECHNICAL OVERVIEW
6.3.2 MARKET DYNAMICS
6.3.3 MARKET ANALYSIS
6.4 MAGNETIC RESONANCE IMAGING (MRI)
6.4.1 TECHNICAL OVERVIEW
6.4.2 MARKET DYNAMICS
6.4.3 MARKET ANALYSIS
6.5 ULTRASOUND
6.5.1 TECHNICAL OVERVIEW
6.5.2 MARKET DYNAMICS
6.5.3 MARKET ANALYSIS
6.6 CATHETERIZATION LABORATORY (CATH LAB)
6.6.1 TECHNICAL OVERVIEW
6.6.2 MARKET DYNAMICS
6.6.3 MARKET ANALYSIS

7 BY INDICATION
7.1 INTRODUCTION
7.2 CARDIOVASCULAR DISORDERS
7.2.1 MARKET DYNAMICS
7.2.2 MARKET ANALYSIS
7.3 NEUROLOGICAL DISORDERS
7.3.1 MARKET DYNAMICS
7.3.2 MARKET ANALYSIS
7.4 RESPIRATORY DISEASES
7.4.1 MARKET DYNAMICS
7.4.2 MARKET ANALYSIS
7.5 GASTROINTESTINAL DISORDERS
7.5.1 MARKET DYNAMICS
7.5.2 MARKET ANALYSIS
7.6 ONCOLOGY
7.6.1 MARKET DYNAMICS
7.6.2 MARKET ANALYSIS
7.7 MUSCULOSKELETAL ANOMALIES
7.7.1 MARKET DYNAMICS
7.7.2 MARKET ANALYSIS
7.8 NEPHROLOGICAL DISORDERS
7.8.1 MARKET DYNAMICS
7.8.2 MARKET ANALYSIS

8 BY APPLICATION
8.1 INTRODUCTION
8.2 RADIOLOGY
8.2.1 TECHNICAL OVERVIEW
8.2.2 MARKET DYNAMICS
8.2.3 MARKET ANALYSIS
8.3 INTERVENTIONAL RADIOLOGY
8.3.1 TECHNICAL OVERVIEW
8.3.2 MARKET DYNAMICS
8.3.3 MARKET ANALYSIS
8.4 INTERVENTIONAL CARDIOLOGY
8.4.1 TECHNICAL OVERVIEW
8.4.2 MARKET DYNAMICS
8.4.3 MARKET ANALYSIS

9 GEOGRAPHIC ANALYSIS
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.3 EUROPE
9.4 ASIA-PACIFIC
9.5 REST OF THE WORLD (ROW)

10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 MERGERS & ACQUISITIONS
10.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
10.4 NEW PRODUCT LAUNCH
10.5 EXPANSION
10.6 APPROVALS
10.7 OTHER DEVELOPMENTS

11 COMPANY PROFILES
(OVERVIEW, FINANCIALS, PRODUCTS & SERVICES, STRATEGY, AND DEVELOPMENTS)* Ø SNAPSHOT
11.1 AMAG PHARMACEUTICALS, INC.
11.2 BAYER HEALTHCARE PHARMACEUTICALS
11.3 BRACCO IMAGING SPA (A SUBSIDIARY OF BRACCO S.P.A)
11.4 COVIDIEN
11.5 CMC CONTRAST AB
11.6 DAIICHI SANKYO CO., LTD.
11.7 GE HEALTHCARE
11.8 GENOVIS AB
11.9 GUERBET GROUP
11.10 LANTHEUS MEDICAL IMAGING, INC.
11.11 NANOPET PHARMA GMBH
11.12 NANOSCAN IMAGING, LLC
11.13 SANOCHEMIA PHARMAZEUTIKA AG
11.14 SPAGO IMAGING AB (A SUBSIDIARY OF ACCELERATOR NORDIC AB)
11.15 SUBHRA PHARMA PRIVATE, LTD
11.16 TAEJOON PHARM CO., LTD.
11.17 TARGESON, INC.
11.18 UNIJULES LIFE SCIENCES, LTD.
*DETAILS ON FINANCIALS, PRODUCT & SERVICES, STRATEGY, AND DEVELOPMENTS MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.